Abstract 1751P
Background
Myxoid liposarcoma (MLPS) constitutes around 15% of all liposarcoma. They are characterized by a specific translocation, the t(12;16), leading to the fusion of FUS to DDIT3, which confers specific molecular features. In this study, we assessed the clinical and survival data of MLPS pts (patients) with evaluation of the impact of various clinical and tumor features on survival outcomes.
Methods
This retrospective study included MLPS pts treated at Gustave Roussy between January 1990 and March 2024. All clinical features were gathered as well as survival data and management details. In addition, we performed univariate (UVA) and multivariate analyses (MVA) to evaluate the impact of various factors on survival (age, gender, adjuvant chemotherapy (CT) and radiation therapy (RT), primary site, and tumor grade (TG)).
Results
336 pts were included (median age of 43 yrs and 60.4% were men). They occurred in the lower arms (75.3%, 253 pts, most in the hip (73.1%)), followed by the trunk (9.8%, 33 pts). TG 1 tumor was in 172 pts (64.7%), TG 2 in 85 (31.9%), and TG 3 in 9 (3.4%). 311 pts had surgery (93.9%) of whom 165 had adjuvant RT (53.1%) while 78 received peri-operative CT (25.1%). Out of 317 pts, 85 had at least one local relapse (LR) (26.8%) with a median time to LR of 24.3 mo. At 6 mo, the LR-free survival (LR-FS) was 96% while the 1- and 5-year LRFS reached 92.2% and 75.8%. 95 had at least one metastatic relapse (MR) (30.3%) with a median time of 38.3 mo. [25.9;45.7]. At 6 mo., the MRFS was 98% while the 1- and 5-year reached 94.8% and 70.6%. The median OS was not reached (NR) [249; NR]. At 6 mo., the OS was 98.8% while the 1- and 5-year were 97.7% and 89.3%. In the UVA, adjuvant RT (p<0.001) and CT (p=0.008) had an impact on LR while in the MVA, adjuvant RT (p<0.001) and age (p=0.03) were significant. Male gender (p=0.01) and high TG (p=0.02) had a higher risk of MR as well as shorter survival (male gender (p=0.04) and TG (p=0.004)).
Conclusions
In one of the largest retrospective cohorts, 336 MLPS pts were commonly diagnosed with a tumor in the lower arms with a localized setting. It is characterized by a high risk of both local (26.8%) and distant relapse (30.3%) but with prolonged survival. Male gender and a higher tumor grade were associated with an increased risk of distant relapse and shorter survival.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1382P - Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
Presenter: Maurice Pérol
Session: Poster session 06
1383P - Distribution of actionable genetic variants in different sample types of Chinese NSCLC: A large real-world data based study
Presenter: Dongmei Lin
Session: Poster session 06
1384P - Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Yuki Sato
Session: Poster session 06
1385P - Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma
Presenter: Mariana Mancini
Session: Poster session 06
1386P - Prognostic value of EGFR A859S alteration in advanced NSCLC patients treated with third-generation EGFR-TKI
Presenter: Wei Xin Zhao
Session: Poster session 06
1387P - Real-world data, tolerability and clinical outcomes in patients with advanced NSCLC treated with sotorasib in the UK
Presenter: Rubab Batool
Session: Poster session 06
1388P - Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster session 06
Resources:
Abstract
1389P - Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease
Presenter: Siddhartha Goutam
Session: Poster session 06
1390P - Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumour
Presenter: Inès Duparc
Session: Poster session 06